Sandoz wrests top generic slot from Teva
The consolidation of the generic drugs industry continues, with Novartis' unit Sandoz merging with two companies that will bring it back into the number one position in the sector.
Archives for February 21, 2005
Pharma and biotech industry thriving in 'new' EU
The pharmaceutical and biotechnology industries in the 'new' EU countries are rapidly expanding, presenting considerable potential, although parallel imports remain a challenge.
Molecular machine to aid drug discovery
A crystallised form of a new molecular machine may lead to new drugs to combat human diseases by using a technique that removes any malfunctioning genes. The thinking is that normal genes can take over without actually changing the genetic code.
Cancer pre-treatment improves drug delivery
Spectrum Pharmaceuticals has licensed a new technology that could enhance the delivery of drugs to tumours, improving the treatment of solid cancers while also reducing side effects.
Cyclacel solve 3-D structures of PCNA complexes
Cyclacel researchers and collaborators have solved the 3-D atomic structure of human Proliferating Cell Nuclear Antigen (PCNA), a protein involved in cancer. The discovery should prove crucial in designing and developing drugs that act on the cancer...
The executive line-up at soon-to-be number one generics company Sandoz – People on the move
In-PharmaTechnologist.com presents a round up of personnel moves in the pharmaceutical sector, including the executive line-up at soon-to-be number one generics company Sandoz.
Starch excipient is soft on tabletting machinery
Cerestar Food & Pharma Specialties Europe has launched an excipient that it claims allows tablets to be produced using lower compression force, which should result in reduced wear and tear on tabletting machinery and operational downtime, writes Phil...
Millennium's antibody-chemotherapeutic shows promise
Millenium Pharmaceuticals has announced final results from a clinical trial of MLN2704, a novel antibody intended for the chemotherapeutic treatment of advanced hormone-refractory prostate cancer.
TZD class emerges as next-gen diabetic treatment
A report into the therapeutics market for diabetics has identified the need for new drug therapies. In addition the report identified significant interest in Amylin's/Lilly's Exenatide and the Thiazolidinedione (TZD) therapeutic class.